Status:
ACTIVE_NOT_RECRUITING
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastat...
Eligibility Criteria
Inclusion
- 1\. Untreated metastatic pancreatic cancer
- 2\. Life expectancy of at least 3 months
- 3\. Patients with ECOG performance status 0 or 1
Exclusion
- 1\. Patients with severe complication
- 2\. Patients with multiple primary cancers
Key Trial Info
Start Date :
July 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06532344
Start Date
July 30 2021
End Date
December 31 2026
Last Update
November 14 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
2
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
3
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, Japan
4
Juntendo University Hospital
Bunkyō-Ku, Tokyo, Japan